[1] A. Chugh and G. L. Bakris. Pulse pressure and arterial stiffness: an emerging renal risk predictor? J. Hypertens, 25:1796–1797, 2017.
[2] Y. Peng-Lin and L. Yue-Chun. Pulse pressure index (pulse pressure/systolic pressure) may be better than pulse pressure for assessment of cardiovascular outcomes. Med. Hypotheses, 72(6):729–731, 2009.
[3] C. Borghi et al. Zofenopril and ramipril in combina[1]tion with acetyl salicylic acid in postmyocardial infarc[1]tion patients with left ventricular systolic dysfunction: A retrospective analysis of the smile-4 randomized , double[1]blind study in diabetic patients. Cardiovascular Thera[1]peutics, 34(2):76–84, 2016.
[4] A. Awada. Primary and secondary prevention of ischemic stroke. J. Med. Liban., 59(4):213–219, 2011.
[5] A. Muthuraman P. Kaur and M. Kaur. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future per[1]spectives. ACS Chem. Neurosci., 6(4):508–521, 2015.
[6] S. G. Vijan. Angiotensin-converting enzyme inhibitors (aceis), not angiotensin receptor blockers (arbs), are pre[1]ferred and effective mode of therapy in high cardiovascu[1]lar risk patients. J. Indian Med. Assoc., 107(3):178–182, 2009.
[7] L. Akioyamen et al. Cardiovascular and cerebrovascu[1]lar outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. J. Am. Soc. Hypertens., 10(1):55–69, 2016.
[8] C. Keller and J. Mueller-Ehmsen. Pharmacological pri[1]mary prevention of myocardial infarction, stroke and death: A possible task? Dtsch. Med. Wochenschr., 141(18):1330–1332, 2016.
[9] S. Foulquier et al. Impact of telmisartan on cardiovas[1]cular outcome in hypertensive patients at high risk: a telmisartan randomised assessment study in ace intoler[1]ant subjects with cardiovascular disease subanalysis. J. Hypertens., 32(6):1334–1341, 2014.
[10] M. Ashwell and S. Gibson. Waist-to-height ratio as an in[1]dicator of early health risk: simpler and more predictive than using a matrixbased on bmi and waist circumfer[1]ence. BMJ Open, 32(6), e010159, 2016.
[11] K. M. Hanus et al. Relationship between gender and clin[1]ical characteristics, associated factors, and hypertension treatment in patients with resistant hypertension. Kar[1]diol. Pol. (Polish Hear. Journal), 75(5):421–431, 2017.
[12] P. Lokaj, J. Parenica, M. P. Goldbergova, K. Helenova, R. Miklik, P. Kubena, and et al. Pulse pressure in clinical practice. Eur. J. Cardiovasc. Med., 2(1):66–68, 2011.
[13] V. Vaccarino, T. R. Holford, and H. M. Krumholz. Pulse pressure and risk for myocardial infarction and heart fail[1]ure in the elderly. J. Am. Coll. Cardiol., 36(1):130–138, 2000.
[14] K. Okada, H. Iso, R. Cui, M. Inoue, and S. Tsugane. Pulse pressure is an independent risk factor for stroke among middle-aged japanese with normal systolic blood pressure the jphc study. J. Hypertens., 29(2):319–324, 2011.
[15] L. Potier et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart, 103(17):1339–1346, 2017.
[16] K. Miura et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovas[1]cular and all-cause mortality rates: The chicago heart association detection project in industry study. Hyper[1]tension, 38(2):232–237, 2001.
[17] T. S. Nawrot et al. Should pulse pressure become part of the framingham risk score?J. Hum. Hypertens., 18(4):279–286, 2004